ArticleJournal of the American College of Surgeons2012
Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Article in Journal of the American College of Surgeons, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Dendritic cell-targeted liposomes for cancer immunotherapy via inhibition of aryl hydrocarbon receptor.Journal of nanobiotechnology · 2025Article
- Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity.Nature nanotechnology · 2024Article
- Knowns and Unknowns about CAR-T Cell Dysfunction.Cancers · 2022Review
- A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.Science immunology · 2022Article
- B cells imprint adoptively transferred CD8Journal for immunotherapy of cancer · 2022Article
- Brief in vitro IL-12 conditioning of CD8Cancer immunology, immunotherapy : CII · 2021Review
- Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Localized Interleukin-12 for Cancer Immunotherapy.Frontiers in immunology · 2020Review
- IFN-γ: A cytokine at the right time, is in the right place.Seminars in immunology · 2019Review
- Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy.Gene therapy · 2019Article
- Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8Cancer research · 2018Article
- Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.Melanoma research · 2018Review
- Platelets subvert T cell immunity against cancer via GARP-TGFβ axis.Science immunology · 2017Article
- Membrane-organizing protein moesin controls Treg differentiation and antitumor immunity via TGF-β signaling.The Journal of clinical investigation · 2017Article
- Harnessing the IL-7/IL-7Rα axis to improve tumor immunotherapy.Oncoimmunology · 2016Article
- Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.Cancer immunology research · 2015Article
- IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.Science translational medicine · 2015Article
- IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.Cancer gene therapy · 2015Article
- Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.Cancer immunology, immunotherapy : CII · 2015Article
- Novel immunotherapies for hematologic malignancies.Immunological reviews · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundClinical application of adoptive T cell therapy has been hindered by an inability to generate adequate numbers of nontolerized, functionally active, tumor-specific T cells, which can persist in vivo. In order to address this, we evaluated the impact of interleukin (IL)-12 signaling during tumor-specific CD8(+) T cell priming in terms of persistence and antitumor efficacy using an established B16 melanoma tumor adoptive therapy model. STUDY
designB6 mice were injected subcutaneously with B16 melanoma tumor cells. On day 12 of tumor growth, mice were preconditioned with cyclophosphamide (4mg dose, intraperitoneally), and 1 day later were treated by adoptive transfer of tumor-specific pmel-1 CD8(+) T cells primed ex vivo 3 days earlier with both IL-12 and antigen (hGP100(25-33) peptide) or antigen only. Tumors were measured biweekly, and infused donor T cells were analyzed for persistence, localization to the tumor, phenotype, and effector function.
resultsAdoptive transfer of tumor-specific CD8(+) T cells primed with IL-12 was significantly more effective in reducing tumor burden in mice preconditioned with cyclophosphamide compared with transfer of T cells primed without IL-12. This enhanced antitumor response was associated with increased frequencies of infused T cells in the periphery and tumor as well as elevated expression of effector molecules including granzyme B and interferon-γ (IFNγ).
conclusionsOur findings demonstrate that ex vivo priming of tumor-specific CD8(+) T cells with IL-12 dramatically improves their in vivo persistence and therapeutic ability on transfer to tumor-bearing mice. These findings can be directly applied as novel clinical trial strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.